Zhongzhi Pharmaceutical Holdings Limited (3737.HK)
HKD 0.94
(0.0%)
HKD 0.94
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 739.3 Million CNY | -14.96% |
| 2022 | 869.3 Million CNY | 39.55% |
| 2021 | 622.94 Million CNY | 4.04% |
| 2020 | 598.75 Million CNY | 15.78% |
| 2019 | 517.15 Million CNY | 69.62% |
| 2018 | 304.89 Million CNY | 25.12% |
| 2017 | 243.67 Million CNY | 30.42% |
| 2016 | 186.84 Million CNY | 16.17% |
| 2015 | 160.84 Million CNY | -9.14% |
| 2014 | 177.02 Million CNY | 12.21% |
| 2013 | 157.76 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 850.02 Million CNY | 14.98% |
| 2023 Q4 | 739.3 Million CNY | 3.9% |
| 2023 FY | 739.3 Million CNY | -14.96% |
| 2023 Q2 | 711.57 Million CNY | -18.15% |
| 2022 FY | 869.3 Million CNY | 39.55% |
| 2022 Q2 | 581.86 Million CNY | -6.59% |
| 2022 Q4 | 869.3 Million CNY | 49.4% |
| 2021 Q2 | 644.03 Million CNY | 7.56% |
| 2021 FY | 622.94 Million CNY | 4.04% |
| 2021 Q4 | 622.94 Million CNY | -3.27% |
| 2020 FY | 598.75 Million CNY | 15.78% |
| 2020 Q4 | 598.75 Million CNY | 7.93% |
| 2020 Q2 | 554.77 Million CNY | 7.27% |
| 2019 FY | 517.15 Million CNY | 69.62% |
| 2019 Q4 | 517.15 Million CNY | 19.57% |
| 2019 Q2 | 432.52 Million CNY | 41.86% |
| 2018 Q4 | 304.89 Million CNY | 20.02% |
| 2018 FY | 304.89 Million CNY | 25.12% |
| 2018 Q2 | 254.04 Million CNY | 4.25% |
| 2017 Q4 | 243.67 Million CNY | 26.49% |
| 2017 Q2 | 192.65 Million CNY | 3.11% |
| 2017 FY | 243.67 Million CNY | 30.42% |
| 2016 Q2 | 171.42 Million CNY | 6.58% |
| 2016 Q4 | 186.84 Million CNY | 9.0% |
| 2016 FY | 186.84 Million CNY | 16.17% |
| 2015 Q4 | 160.84 Million CNY | -15.8% |
| 2015 FY | 160.84 Million CNY | -9.14% |
| 2015 Q2 | 191.02 Million CNY | 7.91% |
| 2014 Q4 | 177.02 Million CNY | 0.0% |
| 2014 FY | 177.02 Million CNY | 12.21% |
| 2013 FY | 157.76 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 142.28 Million HKD | -419.603% |
| Grand Pharmaceutical Group Limited | 7.24 Billion HKD | 89.795% |
| Extrawell Pharmaceutical Holdings Limited | 170.4 Million HKD | -333.845% |
| Wai Yuen Tong Medicine Holdings Limited | 709.65 Million HKD | -4.178% |
| Qianhai Health Holdings Limited | 94 Million HKD | -686.466% |
| Lee's Pharmaceutical Holdings Limited | 930.06 Million HKD | 20.511% |
| Essex Bio-Technology Limited | 903.78 Million HKD | 18.199% |
| Tongfang Kontafarma Holdings Limited | 665.38 Million HKD | -11.108% |
| PuraPharm Corporation Limited | 689.65 Million HKD | -7.199% |
| SSY Group Limited | 4.49 Billion HKD | 83.549% |
| JBM (Healthcare) Limited | 366.75 Million HKD | -101.58% |
| Jacobson Pharma Corporation Limited | 1.09 Billion HKD | 32.205% |
| China Resources Pharmaceutical Group Limited | 168.46 Billion HKD | 99.561% |